Vivimed Labs Ltd Financials
Company Logo

Vivimed Labs Ltd Financial Statement

Vivimed Labs Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue18.30
Operating Expense18.48
Net Profit-5.50
Net Profit Margin-30.05
Earning Per Share-0.66
EBIDTA-0.18
Effective Tax RateTBA

Vivimed Labs Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual103.60
Operating Expenses Annual118.12
Operating Profit Annual-10.33
Interest Annual2.53
Depreciation16.11
Net Profit Annual-31.50
Tax AnnualTBA

Vivimed Labs Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning1.14
Cash Flow from Operations5.73
Cash Flow from Investing-4.06
Cash Flow from Financing-2.53
Cash Flow at the End0.29

Vivimed Labs Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)-9.97
PBIT Margin (%)-27.95
PBT Margin (%)-16.95
Net PROFIT Margin (%)-30.41
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-5.47
Total Debt / Equity (X)10.44
Asset Turnover Ratio (%)0.18

Vivimed Labs Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual315.28
Total Current Assets Annual247.78
Non Current Assets Annual391.18
Total Shareholders Funds Annual58.49
Total Assets Annual638.95

Vivimed Labs Ltd Earning Calls

EPS (INR)

Expected

0.00

Reported

-0.66

Surprise

0.00%

Mar 2025

EPS beaten by 0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

FAQS on Vivimed Labs Ltd Financials

As of Oct 18, 2025, Vivimed Labs Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.

Yes, Vivimed Labs Ltd is not with a debt-to-equity ratio of 6.41.

In FY 2024 , Vivimed Labs Ltd recorded a total revenue of approximately 103.60 Cr marking a significant milestone in the company's financial performance.

Vivimed Labs Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -100.0% and -0.3% annually, respectively..

Vivimed Labs Ltd's current PE ratio is .

Vivimed Labs Ltd's ROCE averaged -18.7% from the FY ending March 2023 to 2025, with a median of -7.2%. It peaked at -5.3% in March 2025, reflecting strong capital efficiency over the period..

Vivimed Labs Ltd's latest EBIT is Rs. -28.97 Cr, surpassing the average EBIT of Rs. -122.10 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions